KYMR — Kymera Therapeutics Inc. stock price and chart

Share this page

KYMR

$104.78-3.11%

as of close, Oct 16, 2026

☾ AH $104.78 -3.11%

Kymera Therapeutics Inc.Stock · HealthcareRussell 2000 0.2%Nasdaq Composite 0.01%US Stock Market 0.01%Russell 3000 0.010%

PeersMRNALLYMDTUNHJNJTMO

Technical analysis2

Overlay lines0

Addendum charts0

Available history since Aug 26, 2020

VolumeEEEE

20202022202320252026

20.030.040.050.060.070.080.090.0100.0110.0120.0010.0M$104.78

2026-10-16

Price$104.78

MA20$113.57

MA50$94.52

Vol3.1M

What would $1,000 invested in KYMR be worth today? →

KYMR returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $104.78
YTD price return: +34.66%
YTD total return: +34.66%
Next earnings: Nov 3, 2026
Market cap: 8.7B2020-09 1.4B2026-10 8.7B+506.1% over the window
Enterprise value: 8.7B
Shares outstanding: 83.2M2019-12 1.9M2026-06 83.2M+4209.4% over the window
52W low: $55.26
52W high: $130.05
From 52W high: -19.43%
From 52W low: +89.61%
52W range: 66%

Volume

Rel volume: 0.60×
30D volume: 817.2K
30D $ vol: 92M

Fundamentals

Sales (ttm): 105M2019-12 2.9M2026-06 105M+3478.7% over the window
Sales/share: $1.262019-12 $1.522026-06 $1.26-17.0% over the window
EPS (ttm): -$3.212020-12 -$3.152026-06 -$3.21+2.0% over the window
FCF (ttm): -238M2019-12 17.4M2026-06 -238M-1469.7% over the window
FCF/share: -$2.862019-12 $9.002026-06 -$2.86-131.8% over the window
Book value/share: $18.152019-12 -$38.562026-06 $18.15-147.1% over the window
Net margin: -285.34%2019-12 -1405.8%2026-06 -285.3%-79.7% over the window
ROE: -19.85%2020-12 -16.1%2026-06 -19.9%+23.6% over the window
ROA: -18.21%2019-12 -35.3%2026-06 -18.2%-48.5% over the window
Current ratio: 10.342019-12 2.692026-06 10.34+284.9% over the window

Growth (CAGR, ttm) · 10Y

Sales: +134.98%2025-06-30 → 2026-06-3044.7M → 105M (+134.8% total)+26.66%2023-06-30 → 2026-06-3051.7M → 105M (+103.2% total)+10.22%2021-06-30 → 2026-06-3064.5M → 105M (+62.7% total)n/a
Shares: +16.31%2025-06-30 → 2026-06-3071.5M → 83.2M (+16.3% total)+14.48%2023-06-30 → 2026-06-3055.4M → 83.2M (+50.1% total)+10.25%2021-06-30 → 2026-06-3051M → 83.2M (+62.9% total)n/a

Per-share growth (CAGR, ttm) · 10Y

Sales/share: +102.03%2025-06-30 → 2026-06-30$0.63 → $1.26 (+101.9% total)+10.63%2023-06-30 → 2026-06-30$0.93 → $1.26 (+35.4% total)-0.03%2021-06-30 → 2026-06-30$1.26 → $1.26 (-0.1% total)n/a
Book value/share: +33.61%2025-06-30 → 2026-06-30$13.59 → $18.15 (+33.6% total)+32.18%2023-06-30 → 2026-06-30$7.86 → $18.15 (+131.0% total)+29.13%2021-06-30 → 2026-06-30$5.06 → $18.15 (+258.9% total)n/a
Price: +73.37%2025-10-16 → 2026-10-16$60.46 → $104.78 (+73.3% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+102.19%2023-10-16 → 2026-10-16$12.67 → $104.78 (+727.0% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+12.86%2021-10-15 → 2026-10-16$57.20 → $104.78 (+83.2% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.n/a
Total return: +73.37%2025-10-16 → 2026-10-16$60.46 → $104.78 (+73.3% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+102.19%2023-10-16 → 2026-10-16$12.67 → $104.78 (+727.0% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+12.86%2021-10-15 → 2026-10-16$57.20 → $104.78 (+83.2% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.n/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: -32.6×2020-09 -34.832026-10 -29.06-16.6% over the window
Fwd P/E: -22.6×
P/S (ttm)Market cap ÷ TTM revenue.: 83.0×2020-09 489.592026-10 82.92-83.1% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 5.8×2020-09 4.872026-10 5.77+18.3% over the window
EV/Sales (ttm): 82.5×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: -2.73%2020-12 2.8%2026-06 -2.5%-187.7% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 83.2M ÷ 71.5M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -16.31%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-16.31%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($3.1B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -16.31%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($8.7B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 0.00%2020-12 0.0%2026-06 0.0%
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $0) ÷ today's market cap ($8.7B). Same caveat as the cash buyback yield.: 0.00%2020-12 0.0%2026-06 0.0%

Vs own 10Y history

P/S: 77th
P/B: 74th

Bar = where today’s multiple sits in KYMR’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-16#

-3.11%

-6.78%

-9.93%

-8.08%

YTD

+34.66%

+73.30%

+83.18%

Financial statements

Open full KYMR financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+10.48%	+0.43%
JNJ	Johnson & Johnson	-4.38%	+0.90%
ABBV	AbbVie Inc.	+8.73%	+0.71%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+6.97%	-1.29%
MRK	Merck & Co. Inc.	+0.72%	+0.52%
NVS	Novartis AG	+8.59%	+0.16%
TMO	Thermo Fisher Scientific Inc.	+6.41%	-0.93%
AMGN	Amgen Inc.	+14.92%	-0.35%

KYMR — Kymera Therapeutics Inc. price, chart and key statistics